Actualités

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know.

Recently, Vertex Pharmaceuticals reported that director Suketu Upadhyay will leave its board at the 2026 annual meeting while the US FDA approved expanded use of ALYFTREK for cystic fibrosis patients aged 6 and older. At the same time, Bank of America reaffirmed Vertex as a top large-cap biotech pick, underscoring how its cystic fibrosis cash flows are supporting a broader pipeline that now includes a rare kidney disease franchise. We’ll now examine how the FDA’s expanded ALYFTREK approval...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Halozyme to continue to outperform expectations and enhance guidance due to strong growth catalysts such as Vyvgart Hytrulo, Darzalex Faspro, […]

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the most profitable biotech stocks to buy now. On April 13, Bank of America reiterated Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as a top large-cap biotech pick for 2026, with a $598 price objective. The firm stated the company’s cystic fibrosis franchise has the ability to generate cash flow to support […]

These longtime market beaters may not have peaked yet.

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for Casgevy, the gene therapy it co-commercializes with Vertex Pharmaceuticals. An interesting angle for investors is how Casgevy’s early commercial uptake and growing treated-patient base may influence perceptions of CRISPR Therapeutics’ broader gene-editing platform and revenue potential. With the...

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.

Revolution Medicines’ stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul.

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive Small Cap valuations, but was impacted by volatility from Middle East geopolitical unrest and changing interest rate expectations. This unrest drove […]